MyoKardia, Inc.
MyoKardia, Inc. (MYOK): 5 pipeline candidates · ~92 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
91.5 months
D/E 0.23 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for MyoKardia, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$675.5M
Quarterly Burn
$29.5M
Runway
91.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| act-1 | Preclinical |
| danicamtiv | Phase 2 |
| lus-1 | Preclinical |
| myk-224 | Preclinical |
| myk-491 | Phase 2 |
Frequently asked questions
How many drug candidates are in MyoKardia, Inc.'s pipeline?
MyoKardia, Inc. (MYOK) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MyoKardia, Inc.'s lead drug candidate?
MyoKardia, Inc.'s most advanced tracked candidate is act-1 (Preclinical) for genetic dilated cardiomyopathy (DCM).
What is MyoKardia, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MyoKardia, Inc. has approximately 91.5 months of cash runway.
Who is the CEO of MyoKardia, Inc.?
South San Francisco is the chief executive officer of MyoKardia, Inc. (MYOK).
Get the full picture on MyoKardia, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.